PATENT 249-119P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

DA CRUZ, Marie et al.

Appl. No.:

New

Group:

Filed:

April 21, 2000

Examiner:

For:

DINITROANILINE LIPSOMAL FORMULATIONS AND

PROCESSES FOR THEIR PREPARATION

INFORMATION DISCLOSURE STATEMENT (SUBMISSION CONCURRENT WITH THE FILING OF A NEW PATENT APPLICATION)

Assistant Commissioner for Patents Washington, DC 20231

April 21, 2000

#### Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

## I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

### II. COPIES

- Submitted herewith is a legible copy of (i) each U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- This application is a National Phase of a PCT application. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should be forwarded from the International Search Authority. If copies are needed, please contact the undersigned.

# III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

#### DOCUMENTS IN THE ENGLISH LANGUAGE

The attached patents, publications, or other information in the English language do not require a statement of relevancy.

## b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

#### c. M ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A)(3).

#### d. Tother

The following additional information is provided for the Examiner's consideration.

#### FEES

This Information Disclosure Statement is being filed concurrently with the filing of a new patent application; therefore, no fee is required.

If The Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

Joseph A. Kolasch, #22,463

JAK/cqc 249-119P P.O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000

PHCTOSULES.	Encl	osures	:
-------------	------	--------	---

Documents

Foreign Search Report

□ Fee

Other: International Search Report

(Rev. 04/19/2000)

New 09/529937 ATTY DOCKET NO. Form PTO-1449 249-119P INFORMATION DISCLOSURE CITATION APPLICANT DA CRUZ, Maria et al. IN AN APPLICATION FILING DATE GROUP (Use several sheets if necessary) April 21, 2000 U.S. PATENT DOCUMENTS DOCUMENT NUMBER DATE NAME FOREIGN PATENT DOCUMENTS DOCUMENT NUMBER DATE COUNTRY SUB 1995-11-30 WO A9 5 3 0 1 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Gennaro et al., Remington's Pharmaceutical Sciences, Vol. 17, pp. 1659-1660 (1985)DATE CONSIDERED EXAMINER EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.